

AGENDA

***Uniform Formulary Beneficiary Advisory Panel
30 July 2009 @ 10:00 AM***

***Naval Heritage Center Theater
701 Pennsylvania Ave. NW., Washington DC 20004***

- **Administrative Meeting (BAP members only @ 8:30 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DoD Pharmacoeconomic Center will present relative clinical and cost effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations of the following drug classes during the May 2009 meeting:

- ***Designated Newly Approved Drugs***
 - *Antilipidemic –II Agents – Fenofibrate acid capsules (Trilipix)*
 - *Overactive Bladder Drugs - Fesoterodine extended release tablets (Toviaz)*
 - *Nasal Allergy Drugs – Azelastine with sucralose nasal spray (Astepro)*
 - *Proton Pump Inhibitors – Dexlansoprazole delayed release capsules (Kapidex)*
 - *Antidepressant I Agents – Venlafaxine Extended Release Tablets*
 - *Antiemetics – Granisetron transdermal system (Sancuso)*
- **Panel Discussions**

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.